"Idarubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.
| Descriptor ID |
D015255
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.300 D04.615.562.050.200.300 D09.408.051.059.200.300
|
| Concept/Terms |
Idarubicin- Idarubicin
- 4-Desmethoxydaunorubicin
- 4 Desmethoxydaunorubicin
- 4-Demethoxydaunorubicin
- 4 Demethoxydaunorubicin
|
Below are MeSH descriptors whose meaning is more general than "Idarubicin".
Below are MeSH descriptors whose meaning is more specific than "Idarubicin".
This graph shows the total number of publications written about "Idarubicin" by people in this website by year, and whether "Idarubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Idarubicin" by people in Profiles.
-
Outcome of a patient with refractory Hodgkin lymphoma on pembrolizumab, infected with SARS-CoV-2. Br J Haematol. 2020 Jul; 190(1):e1-e3.
-
A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients. Leuk Res. 2019 01; 76:1-10.
-
Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood. 2018 07 26; 132(4):405-412.
-
Release of Danger-Associated Molecular Patterns following Chemotherapy Does Not Induce Immunoparalysis in Leukemia Patients. Acta Haematol. 2017; 138(1):39-43.
-
A life-threatening ruxolitinib discontinuation syndrome. Am J Hematol. 2017 08; 92(8):833-838.
-
A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood 'high-risk' acute lymphoblastic leukaemia: a study of the AIEOP group. Br J Haematol. 2002 Sep; 118(3):741-7.